Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.46 |
| ▸ | GRM3 | Q14832 | 4/20 | 0.46 |
| ▸ | PPP5C | P53041 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967009 | 1.00 | POLB (0.53) | POLBTDP1CTDSP1GRM2GRM3 | |
| SCHEMBL11049187 | 1.00 | POLB (0.53) | POLBTDP1CTDSP1GRM2GRM3 | |
| SCHEMBL26342164 | 1.00 | POLB (0.53) | POLBTDP1CTDSP1GRM2GRM3 | |
| SCHEMBL8954735 | 1.00 | POLB (0.53) | POLBTDP1CTDSP1GRM2GRM3 | |
| SCHEMBL8954745 | 1.00 | POLB (0.53) | POLBTDP1CTDSP1GRM2GRM3 | |
| SCHEMBL15514425 | 0.96 | POLB (0.50) | POLBTDP1CTDSP1GRM2GRM3 | |
| SCHEMBL15182531 | 0.96 | POLB (0.50) | POLBTDP1CTDSP1GRM2GRM3 | |
| SCHEMBL6031523 | 0.92 | POLB (0.53) | POLBTDP1CTDSP1GRM2GRM3 | |
| SCHEMBL992359 | 0.92 | POLB (0.53) | POLBTDP1CTDSP1GRM2GRM3 | |
| SCHEMBL12763432 | 0.89 | POLB (0.50) | POLBTDP1CTDSP1GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070007489-A1 | Heat transfer medium composition | SHISHIAI-KABUSHIKIGAISHA (JP) | 2007-01-11 | — | — | US | claimed |
| EP-1698678-A1 | HEAT CARRIER COMPOSITION | Shishiai-Kabushikigaisha (JP) | 2006-09-06 | — | — | EP | claimed |
| CN-113717062-A | Compound, polymer, liquid crystal aligning agent, liquid crystal alignment film, liquid crystal display element, and production method | 捷恩智株式会社 | 2021-11-30 | — | — | CN | disclosed |
| US-20130026047-A1 | METHOD AND APPARATUS FOR ELECTROLYTIC SURFACE ROUGHENING TREATMENT AND METHOD AND APPARATUS FOR MANUFACTURING PLANOGRAPHIC PRINTING PLATE PRECURSOR | FUJIFILM CORPORATION (JP) | 2013-01-31 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1935887-B1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070007489-A1 | Heat transfer medium composition | SHISHIAI-KABUSHIKIGAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1392676-B1 | HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1698678-A1 | HEAT CARRIER COMPOSITION | Shishiai-Kabushikigaisha (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1688412-A2 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-4141911-A | REACTING DICARBOXYLIC ACID WITH MONOBASIC CHROMIC SALT, SURFACTANTS | TOKYO SHIBAURA ELECTRIC CO., LTD. (JP) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | POLB 3936/4885TDP1 1443/4885CTDSP1 3374/4885 |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | POLB 3936/4885TDP1 1443/4885CTDSP1 3374/4885 |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | DRD3, DRD2, HTR3C | POLB 3932/4885TDP1 1274/4885CTDSP1 3886/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | POLB 3901/4885TDP1 1324/4885CTDSP1 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.